Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

On heels of debt financing, Omeros completes $38.1mm FOPO

Executive Summary

Just weeks after receiving $32mm in debt financing from Oxford Finance and MidCap Financial, Omeros Corp. (low-dose combinations of existing drugs for various disease) publicly sold 3.5mm shares (including the overallotment) at $11.50 to net $38.1mm.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies